Evidence of Thymic Function in Heavily Antiretroviral‐Treated Human Immunodeficiency Virus Type 1–Infected Adults with Long‐Term Virologic Treatment Failure
1Viral Hepatitis and AIDS Study Group, Department of Internal Medicine, and 2Department of Radiology, Virgen del Rocío University Hospital, Seville, Spain
Thymic function was evaluated in 32 heavily antiretroviral‐treated human immunodeficiency virus type 1 (HIV‐1)–infected adults with long‐term virologic treatment failure by measuring thymic volume, by determining the absolute number of naive T cell phenotypes, and by determining the number of cells carrying T cell receptor excision circles (TRECs). There was a significant inverse correlation between age and thymic volume (
;
), and there was a significant direct correlation between thymic volume and total naive T cell counts (
;
), naive CD4+ cell counts (
;
), naive CD8+ cell counts (
;
), and TREC levels (
;
). In conclusion, this study found clear evidence that the thymus of heavily antiretroviral‐treated HIV‐1–infected adults with long‐term virologic treatment failure is actively engaged in thymopoiesis, which generates new naive T cells for the peripheral lymphocyte pool.
Received 16 November 2001; revised 5 April 2002; electronically published 5 July 2002.
Cited by
Online publication date: 1-Feb-2008.
CrossRef
Online publication date: 1-Nov-2005.
Online publication date: 1-Oct-2005.
CrossRef
Online publication date: 1-Jul-2004.
CrossRef
Online publication date: 1-Mar-2004.
CrossRef
Online publication date: 1-Feb-2004.
CrossRef
-
This study was designed and performed according to the Helsinki Declaration and was approved by the Ethical Committee of the University Hospital Virgen del Rocío of Seville (Spain). All patients gave written informed consent to participate in this cross‐sectional study.
Financial support: Fondo de Investigaciones Sanitarias (FIS 00/0521); Fondo para la Investigación y Prevención del SIDA en España (FIPSE 2132/00, including Ministerio de Sanidad y Consumo, Abbott Laboratories, Boehringer Ingelgeim, Bristol Myers Squibb, GlaxoSmithKline, Merck Sharp and Dohme, and Roche); Fundación Wellcome España.





